RGD Reference Report - MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway.

Authors: Sun, Lu  Guo, Zhixian  Sun, Jihong  Li, Jingjing  Dong, Zihui  Zhang, Yize  Chen, Jianan  Kan, Quancheng  Yu, Zujiang 
Citation: Sun L, etal., Biomed Pharmacother. 2018 Nov;107:168-176. doi: 10.1016/j.biopha.2018.07.151. Epub 2018 Aug 6.
RGD ID: 153344517
Pubmed: PMID:30086463   (View Abstract at PubMed)
DOI: DOI:10.1016/j.biopha.2018.07.151   (Journal Full-text)

Hepatocellular carcinoma (HCC), one of the most common maligant cancers in the world, is difficult to diagnose in the early time. MicroRNAs (miRNAs), small non-coding RNAs, perform vital functions in cellular differentiation, metabolism and physiological processes. MiR-133a acts as a tumor suppressor in breast, lung and gastric cancer, while the molecular circadian mechanism has not been clear in HCC. In the present study, we certified that the expression of miR-133a decreased in HCC tissues and cell lines and that miR-133a inhibited proliferation, migration and invasion of hepatocellular carcinoma cells. Fos-related antigen 2 (FOSL2), also named FRA-2, was predicted to be a downstream target of miR-133a based on bioinformatic analysis and the prediction was verified by Western Blot, qRT-PCR and luciferase reporter assay. In addition, there was a negative correlation between miR-133a and FOSL2 expression in HCC samples. Furthermore, we verified that overexpression of miR-133a suppressed biological behaviour of HCC through TGF-β/Smad3 signaling pathway. In brief, miR-133a may be a potential prognostic biomarker and may thus be a new therapy in HCC.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
hepatocellular carcinoma  IEP 153344517mRNA:increased expression:liver (human)RGD 
hepatocellular carcinoma  ISOFOSL2 (Homo sapiens)153344517; 153344517mRNA:increased expression:liver (human)RGD 
hepatocellular carcinoma disease_progressionIEP 153344517mRNA:decreased expression:liver (human)RGD 
hepatocellular carcinoma  IMP 153344517human cells in mouse modelRGD 
hepatocellular carcinoma disease_progressionISOMIR133A1 (Homo sapiens)153344517; 153344517mRNA:decreased expression:liver (human)RGD 
hepatocellular carcinoma  ISOMIR133A1 (Homo sapiens)153344517; 153344517human cells in mouse modelRGD 

Objects Annotated

Genes (Rattus norvegicus)
Fosl2  (FOS like 2, AP-1 transcription factor subunit)
Mir133a1  (microRNA 133a-1)

Genes (Mus musculus)
Fosl2  (fos-like antigen 2)
Mir133a-1  (microRNA 133a-1)

Genes (Homo sapiens)
FOSL2  (FOS like 2, AP-1 transcription factor subunit)
MIR133A1  (microRNA 133a-1)


Additional Information